开云app官网登录入口网页版-官方正版

#依那西普#

27篇内容 | 2115人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2126904, encodeId=0130212690456, content=<a href='/topic/show?id=e4ed2693895' target=_blank style='color:#2F92EE;'>#依那西普#</a>减量治疗<a href='/topic/show?id=7face61750b' target=_blank style='color:#2F92EE;'>#类风湿性关节炎#</a>、<a href='/topic/show?id=d38b501864f' target=_blank style='color:#2F92EE;'>#强直性脊柱炎#</a>和<a href='/topic/show?id=5a64966325c' target=_blank style='color:#2F92EE;'>#银屑病关节炎#</a>的疗效，未来还可以考虑<a href='/topic/show?id=db961059298d' target=_blank style='color:#2F92EE;'>#梯度减量#</a>的方法，总之可以不断优化，以达到效果, objectTitle=Scand J Rheumatol：依那西普减量治疗类风湿性关节炎、强直性脊柱炎和银屑病关节炎的疗效, objectType=article, longId=765706, objectId=dbf2e65706d0, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20230326/1679868291138_4754896.png, objectUrl=/article/show_article.do?id=dbf2e65706d0, replyNumber=0, likeNumber=0, createdTime=2023-04-18, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=香港, moduleDTOList=[ModuleDTO(moduleId=dbf2e65706d0, moduleTitle=Scand J Rheumatol：依那西普减量治疗类风湿性关节炎、强直性脊柱炎和银屑病关节炎的疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=dbf2e65706d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2117621, encodeId=89ad211e6212e, content=<a href='/topic/show?id=d38b501864f' target=_blank style='color:#2F92EE;'>#强直性脊柱炎#</a>（AS）传统治疗策略仅限于非甾体抗炎药、糖皮质激素等药物。TNFi已被证明能有效改善AS患者的腰椎前凸畸形。目前可用于临床治疗AS的TNFi主要包括<a href='/topic/show?id=8eeb8e122c6' target=_blank style='color:#2F92EE;'>#英夫利昔单抗#</a>（infliximab，IFX）、<a href='/topic/show?id=ada39e9465a' target=_blank style='color:#2F92EE;'>#阿达木单抗#</a>（adalimumab，ADA）、<a href='/topic/show?id=4f465380215' target=_blank style='color:#2F92EE;'>#戈利木单抗#</a>（golimumab，GOL）以及<a href='/topic/show?id=e4ed2693895' target=_blank style='color:#2F92EE;'>#依那西普#</a>（Enbrel，ETN）等。, objectTitle=浅谈强直性脊柱炎相关生物制剂和小分子靶向药治疗进展, objectType=article, longId=761626, objectId=d026e61626ad, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20230304/1677928811259_5295905.jpg, objectUrl=/article/show_article.do?id=d026e61626ad, replyNumber=0, likeNumber=130, createdTime=2023-03-05, rootId=0, userName=lifestar, userId=aa0e14, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=d026e61626ad, moduleTitle=浅谈强直性脊柱炎相关生物制剂和小分子靶向药治疗进展, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d026e61626ad)], followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=1340455, encodeId=650e134045550, content=<a href='/topic/show?id=e4ed2693895' target=_blank style='color:#2F92EE;'>#依那西普#</a>, objectTitle=Arthritis Rheumatol：托西利珠单抗VS依那西普在类风湿关节炎中的心血管安全性, objectType=article, longId=198545, objectId=0a21198545d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a21198545d5, replyNumber=0, likeNumber=70, createdTime=2020-08-03, rootId=0, userName=ms1490123962508630, userId=ca772500164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a21198545d5, moduleTitle=Arthritis Rheumatol：托西利珠单抗VS依那西普在类风湿关节炎中的心血管安全性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0a21198545d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1340454, encodeId=85d91340454ba, content=<a href='/topic/show?id=e4ed2693895' target=_blank style='color:#2F92EE;'>#依那西普#</a>, objectTitle=重磅！依那西普治愈了法国COVID-19患者, objectType=article, longId=194063, objectId=8bb5194063f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8bb5194063f8, replyNumber=0, likeNumber=80, createdTime=2020-05-14, rootId=0, userName=ms1490123962508630, userId=ca772500164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8bb5194063f8, moduleTitle=重磅！依那西普治愈了法国COVID-19患者, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8bb5194063f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1340453, encodeId=c1fe13404531b, content=<a href='/topic/show?id=e4ed2693895' target=_blank style='color:#2F92EE;'>#依那西普#</a>, objectTitle=Ann Rheum Dis：超早期使用依那西普和MTX vs MTX联合依那西普延迟治疗RA的随机对照试验, objectType=article, longId=188894, objectId=dc6f18889404, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc6f18889404, replyNumber=0, likeNumber=75, createdTime=2020-02-29, rootId=0, userName=ms1490123962508630, userId=ca772500164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc6f18889404, moduleTitle=Ann Rheum Dis：超早期使用依那西普和MTX vs MTX联合依那西普延迟治疗RA的随机对照试验, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=dc6f18889404)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1340452, encodeId=11291340452be, content=<a href='/topic/show?id=e4ed2693895' target=_blank style='color:#2F92EE;'>#依那西普#</a>, objectTitle=Arthritis Rheumatol：依那西普和甲氨蝶呤单药或联合用药治疗银屑病关节炎的疗效, objectType=article, longId=160634, objectId=856e1606342d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=856e1606342d, replyNumber=0, likeNumber=172, createdTime=2019-02-22, rootId=0, userName=ms1490123962508630, userId=ca772500164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=856e1606342d, moduleTitle=Arthritis Rheumatol：依那西普和甲氨蝶呤单药或联合用药治疗银屑病关节炎的疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=856e1606342d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1340451, encodeId=32511340451e3, content=<a href='/topic/show?id=e4ed2693895' target=_blank style='color:#2F92EE;'>#依那西普#</a>, objectTitle=Ann Rheum Dis：换药或不换药？从初始药强制换为依那西普生物仿制药全国性指南的结果, objectType=article, longId=153505, objectId=e6e515350516, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6e515350516, replyNumber=0, likeNumber=66, createdTime=2018-11-16, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6e515350516, moduleTitle=Ann Rheum Dis：换药或不换药？从初始药强制换为依那西普生物仿制药全国性指南的结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e6e515350516)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1340450, encodeId=01511340450f2, content=<a href='/topic/show?id=e4ed2693895' target=_blank style='color:#2F92EE;'>#依那西普#</a>, objectTitle=Ann Rheum Dis：依那西普对炎症性手部骨关节炎的疗效（EHOA）, objectType=article, longId=150393, objectId=37c2150393b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=37c2150393b8, replyNumber=0, likeNumber=100, createdTime=2018-10-07, rootId=0, userName=ms1490123962508630, userId=ca772500164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=37c2150393b8, moduleTitle=Ann Rheum Dis：依那西普对炎症性手部骨关节炎的疗效（EHOA）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=37c2150393b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1340449, encodeId=0c86134044938, content=<a href='/topic/show?id=e4ed2693895' target=_blank style='color:#2F92EE;'>#依那西普#</a>, objectTitle=Semin Arthritis Rheu：依那西普浓度和免疫原性不会影响幼年特发性关节炎患者对依那西普的反应, objectType=article, longId=149187, objectId=d27d14918ef6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d27d14918ef6, replyNumber=0, likeNumber=72, createdTime=2018-09-22, rootId=0, userName=ms1490123962508630, userId=ca772500164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d27d14918ef6, moduleTitle=Semin Arthritis Rheu：依那西普浓度和免疫原性不会影响幼年特发性关节炎患者对依那西普的反应, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d27d14918ef6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1340448, encodeId=257213404488d, content=<a href='/topic/show?id=e4ed2693895' target=_blank style='color:#2F92EE;'>#依那西普#</a>, objectTitle=Clover制药在中国启动依那西普生物仿制药的I期试验, objectType=article, longId=145739, objectId=a66f145e39d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a66f145e39d1, replyNumber=0, likeNumber=95, createdTime=2018-08-04, rootId=0, userName=ms1490123962508630, userId=ca772500164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a66f145e39d1, moduleTitle=Clover制药在中国启动依那西普生物仿制药的I期试验, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a66f145e39d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1340447, encodeId=16f6134044e69, content=<a href='/topic/show?id=e4ed2693895' target=_blank style='color:#2F92EE;'>#依那西普#</a>, objectTitle=Semin Arthritis Rheu：从原研药转为生物仿制药依那西普（SB4）的接受率和所涉及的社会学因素, objectType=article, longId=145029, objectId=be031450298b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be031450298b, replyNumber=0, likeNumber=60, createdTime=2018-07-25, rootId=0, userName=ms1490123962508630, userId=ca772500164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be031450298b, moduleTitle=Semin Arthritis Rheu：从原研药转为生物仿制药依那西普（SB4）的接受率和所涉及的社会学因素, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=be031450298b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1340446, encodeId=83e41340446e2, content=<a href='/topic/show?id=e4ed2693895' target=_blank style='color:#2F92EE;'>#依那西普#</a>, objectTitle=J Rheumatol：幼年特发性关节炎患者依那西普停药后急性发作的预测因子, objectType=article, longId=137802, objectId=299f13e80284, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=299f13e80284, replyNumber=0, likeNumber=89, createdTime=2018-05-12, rootId=0, userName=ms1490123962508630, userId=ca772500164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=299f13e80284, moduleTitle=J Rheumatol：幼年特发性关节炎患者依那西普停药后急性发作的预测因子, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=299f13e80284)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1340445, encodeId=620213404458d, content=<a href='/topic/show?id=e4ed2693895' target=_blank style='color:#2F92EE;'>#依那西普#</a>, objectTitle=非布司他联合依那西普治疗难治性痛风1例, objectType=article, longId=136620, objectId=0c901366208c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c901366208c, replyNumber=0, likeNumber=68, createdTime=2018-04-28, rootId=0, userName=ms1490123962508630, userId=ca772500164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c901366208c, moduleTitle=非布司他联合依那西普治疗难治性痛风1例, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0c901366208c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1340444, encodeId=c65c134044480, content=<a href='/topic/show?id=e4ed2693895' target=_blank style='color:#2F92EE;'>#依那西普#</a>, objectTitle=Ann Rheum Dis： LBEC0101和依那西普对甲氨蝶呤反应不良性活动类风湿关节炎患者疗效和安全性的III期研究, objectType=article, longId=124092, objectId=25b012409255, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25b012409255, replyNumber=0, likeNumber=124, createdTime=2017-12-22, rootId=0, userName=ms1490123962508630, userId=ca772500164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25b012409255, moduleTitle=Ann Rheum Dis： LBEC0101和依那西普对甲氨蝶呤反应不良性活动类风湿关节炎患者疗效和安全性的III期研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=25b012409255)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1340443, encodeId=8dc3134044395, content=<a href='/topic/show?id=e4ed2693895' target=_blank style='color:#2F92EE;'>#依那西普#</a>, objectTitle=Pharmacoepidemiol Drug Saf：cIA或PsO女性：依那西普对妊娠和婴儿结局有影响吗？, objectType=article, longId=117736, objectId=d3b911e73638, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3b911e73638, replyNumber=0, likeNumber=85, createdTime=2017-10-28, rootId=0, userName=ms1490123962508630, userId=ca772500164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3b911e73638, moduleTitle=Pharmacoepidemiol Drug Saf：cIA或PsO女性：依那西普对妊娠和婴儿结局有影响吗？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d3b911e73638)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1340442, encodeId=790e134044253, content=<a href='/topic/show?id=e4ed2693895' target=_blank style='color:#2F92EE;'>#依那西普#</a>, objectTitle=ANN RHEUM DIS：类风湿关节炎维持SB4治疗或从依那西普转为SB4的长期疗效和安全性, objectType=article, longId=108523, objectId=0689108523b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0689108523b9, replyNumber=0, likeNumber=74, createdTime=2017-08-13, rootId=0, userName=ms1490123962508630, userId=ca772500164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0689108523b9, moduleTitle=ANN RHEUM DIS：类风湿关节炎维持SB4治疗或从依那西普转为SB4的长期疗效和安全性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0689108523b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1340441, encodeId=be14134044152, content=<a href='/topic/show?id=e4ed2693895' target=_blank style='color:#2F92EE;'>#依那西普#</a>, objectTitle=J Rheumatol：依那西普治疗对银屑病关节炎心血管危险因素的影响, objectType=article, longId=101342, objectId=874510134267, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=874510134267, replyNumber=0, likeNumber=88, createdTime=2017-06-11, rootId=0, userName=ms1490123962508630, userId=ca772500164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=874510134267, moduleTitle=J Rheumatol：依那西普治疗对银屑病关节炎心血管危险因素的影响, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=874510134267)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1340440, encodeId=65b3134044062, content=<a href='/topic/show?id=e4ed2693895' target=_blank style='color:#2F92EE;'>#依那西普#</a>, objectTitle=喜讯！默沙东与三星依那西普生物仿制药Brenzys获加拿大卫生部批准, objectType=article, longId=77800, objectId=ebc8e780028, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ebc8e780028, replyNumber=0, likeNumber=115, createdTime=2016-09-20, rootId=0, userName=ms1490123962508630, userId=ca772500164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ebc8e780028, moduleTitle=喜讯！默沙东与三星依那西普生物仿制药Brenzys获加拿大卫生部批准, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ebc8e780028)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1340439, encodeId=99bc134043927, content=<a href='/topic/show?id=e4ed2693895' target=_blank style='color:#2F92EE;'>#依那西普#</a>, objectTitle=2010PRAJ指南——应用依那西普治疗幼年特发性关节炎发布, objectType=article, longId=73988, objectId=4a93e398831, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a93e398831, replyNumber=0, likeNumber=65, createdTime=2016-07-30, rootId=0, userName=ms1490123962508630, userId=ca772500164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a93e398831, moduleTitle=2010PRAJ指南——应用依那西普治疗幼年特发性关节炎发布, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=4a93e398831)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1340438, encodeId=c4e5134043833, content=<a href='/topic/show?id=e4ed2693895' target=_blank style='color:#2F92EE;'>#依那西普#</a>, objectTitle=Ann Rheum Dis：依那西普与强直性脊柱炎活动性的关系, objectType=article, longId=57924, objectId=99ca5e9242d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=99ca5e9242d, replyNumber=0, likeNumber=70, createdTime=2015-10-29, rootId=0, userName=ms1490123962508630, userId=ca772500164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=99ca5e9242d, moduleTitle=Ann Rheum Dis：依那西普与强直性脊柱炎活动性的关系, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=99ca5e9242d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

依那西普

2020-05-29

侠胆医心 (审核中...)

前往app查看评论内容

#依那西普#减量治疗#类风湿性关节炎#、#强直性脊柱炎#和#银屑病关节炎#的疗效，未来还可以考虑#梯度减量#的方法，总之可以不断优化，以达到效果

Scand J Rheumatol：依那西普减量治疗类风湿性关节炎、强直性脊柱炎和银屑病关节炎的疗效

2023-04-18发表于香港

lifestar (审核中...)

前往app查看评论内容

全文收起 #强直性脊柱炎#（AS）传统治疗策略仅限于非甾体抗炎药、糖皮质激素等药物。TNFi已被证明能有效改善AS患者的腰椎前凸畸形。目前可用于临床治疗AS的TNFi主要包括#英夫利昔单抗#（infliximab，IFX）、#阿达木单抗#（adalimumab，ADA）、#戈利木单抗#（golimumab，GOL）以及#依那西普#（Enbrel，ETN）等。

浅谈强直性脊柱炎相关生物制剂和小分子靶向药治疗进展

2023-03-05发表于上海

ms1490123962508630 (审核中...)

前往app查看评论内容

#依那西普#

Arthritis Rheumatol：托西利珠单抗VS依那西普在类风湿关节炎中的心血管安全性

2020-08-03

ms1490123962508630 (审核中...)

前往app查看评论内容

#依那西普#

重磅！依那西普治愈了法国COVID-19患者

2020-05-14

ms1490123962508630 (审核中...)

前往app查看评论内容

#依那西普#

Ann Rheum Dis：超早期使用依那西普和MTX vs MTX联合依那西普延迟治疗RA的随机对照试验

2020-02-29

ms1490123962508630 (审核中...)

前往app查看评论内容

#依那西普#

Arthritis Rheumatol：依那西普和甲氨蝶呤单药或联合用药治疗银屑病关节炎的疗效

2019-02-22

医者仁心 (审核中...)

前往app查看评论内容

#依那西普#

Ann Rheum Dis：换药或不换药？从初始药强制换为依那西普生物仿制药全国性指南的结果

2018-11-16

ms1490123962508630 (审核中...)

前往app查看评论内容

#依那西普#

Ann Rheum Dis：依那西普对炎症性手部骨关节炎的疗效（EHOA）

2018-10-07

ms1490123962508630 (审核中...)

前往app查看评论内容

#依那西普#

Semin Arthritis Rheu：依那西普浓度和免疫原性不会影响幼年特发性关节炎患者对依那西普的反应

2018-09-22

ms1490123962508630 (审核中...)

前往app查看评论内容

#依那西普#

Clover制药在中国启动依那西普生物仿制药的I期试验

2018-08-04

ms1490123962508630 (审核中...)

前往app查看评论内容

#依那西普#

Semin Arthritis Rheu：从原研药转为生物仿制药依那西普（SB4）的接受率和所涉及的社会学因素

2018-07-25

ms1490123962508630 (审核中...)

前往app查看评论内容

#依那西普#

J Rheumatol：幼年特发性关节炎患者依那西普停药后急性发作的预测因子

2018-05-12

ms1490123962508630 (审核中...)

前往app查看评论内容

#依那西普#

非布司他联合依那西普治疗难治性痛风1例

2018-04-28

ms1490123962508630 (审核中...)

前往app查看评论内容

#依那西普#

Ann Rheum Dis： LBEC0101和依那西普对甲氨蝶呤反应不良性活动类风湿关节炎患者疗效和安全性的III期研究

2017-12-22

ms1490123962508630 (审核中...)

前往app查看评论内容

#依那西普#

Pharmacoepidemiol Drug Saf：cIA或PsO女性：依那西普对妊娠和婴儿结局有影响吗？

2017-10-28

ms1490123962508630 (审核中...)

前往app查看评论内容

#依那西普#

ANN RHEUM DIS：类风湿关节炎维持SB4治疗或从依那西普转为SB4的长期疗效和安全性

2017-08-13

ms1490123962508630 (审核中...)

前往app查看评论内容

#依那西普#

J Rheumatol：依那西普治疗对银屑病关节炎心血管危险因素的影响

2017-06-11

ms1490123962508630 (审核中...)

前往app查看评论内容

#依那西普#

喜讯！默沙东与三星依那西普生物仿制药Brenzys获加拿大卫生部批准

2016-09-20

ms1490123962508630 (审核中...)

前往app查看评论内容

#依那西普#

2010PRAJ指南——应用依那西普治疗幼年特发性关节炎发布

2016-07-30

ms1490123962508630 (审核中...)

前往app查看评论内容

#依那西普#

Ann Rheum Dis：依那西普与强直性脊柱炎活动性的关系

2015-10-29

科室
- - 订阅+
  - 更多科室
工具
服务